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Abstract
Background Doxorubicin (DOX) is a small molecular cyto-
toxic agent that can be transferred efficiently to cancer cells by
nanocarriers. This anthracycline antibiotic serves as an effec-
tive anti-neoplastic drug against both hematological and solid
malignancies. Here, we set out to assess the capacity of a
novel doxorubicin - transferrin conjugate (DOX-TRF) to pro-
voke apoptosis in human normal and leukemia cells through
free radicals produced via a redox cycle of doxorubicin
(DOX) when released from its conjugate.
Methods After DOX-TRF exposure, we determined the time-
course of apoptotic and necrotic events, the generation of re-
active oxygen species (ROS), changes in mitochondrial mem-
brane potential, as well as alterations in cytochrome c levels
and intracellular calcium concentrations in human leukemia-
derived cell lines (CCRF-CEM, K562 and its doxorubicin-
resistant derivative K562/DOX) and normal peripheral
blood-derived mononuclear cells (PBMC).
Results We found that DOX-TRF can induce apoptosis in all
leukemia-derived cell lines tested, which was associated with
morphological changes and decreases in mitochondrial mem-
brane potential. In comparison to free DOX treated cells, we
observed a time-dependency between a higher level of ROS
generation and a higher drop in mitochondrial membrane po-
tential, particularly in the doxorubicin-resistant cell line. In
addition, we found that the apoptotic cell death induced by
DOX-TRF was directly associated with a release of cyto-
chrome c from the mitochondria and an increase in intracellu-
lar calcium level in all human leukemia-derived cell lines
tested.
Conclusions Our data indicate that DOX-TRF is considerably
more cytotoxic to human leukemia cells than free DOX. In
addition, we show that DOX-TRF can effectively produce free
radicals, which are directly involved in apoptosis induction.
Keywords Doxorubicin-transferrin conjugate . Anticancer
therapy . ROS generation . Leukemia cells .Mitochondrial
membrane potential
1 Introduction
During the last 15 years, numerous peptides and proteins have
been used for improving the transport of cytotoxic agents.
Chemical modifications of conventional chemotherapeutics
provide novel possibilities for enhancing their limited clinical
success so far, which may be due to tumor heterogeneity and
the emergence of drug resistance. Several approaches have
been tested, including drug entrapment in carriers like lipo-
somes [1], polymeric micelles [2] and nanoparticles [3; 4].
More recent efforts have focused on the identification of
new vehicles for intracellular delivery, such as lactosaminated
human albumin [3] and transferrin [4].
Highlights
?1. DOX-TRF conjugate induced larger changes in the level of reactive
oxygen species than free DOX.
2. DOX-TRF-generated free radicals led to a decrease of mitochondrial
damage.
3. Leukemia cells incubated with conjugate died more prevalently by
apoptosis than by necrosis.
4. DOX-TRF conjugate may be a candidate for evaluation as a
chemotherapeutic agent for human leukemia.
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A small molecular cytotoxic agent that can be trans-
ferred efficiently to cancer cells by nanocarriers is doxo-
rubicin (DOX). This anthracycline antibiotic is an effec-
tive anti-neoplastic drug against both hematological ma-
lignancies and solid tumors [5]. The mechanism of DOX
action has been linked to DNA damage, topoisomerase
inhibition and iron sequestration with subsequent free rad-
ical generation [6–8]. However, its nonspecific distribu-
tion, leading to intolerable adverse effects and the devel-
opment of drug resistance, still limits the current use of
DOX.
Polymer-based delivery systems that have been devel-
oped for DOX are mostly designed to direct DOX away
from sites of drug toxicity, especially the heart, and towards
the site of drug action, i.e., the tumor [9, 10]. These deliv-
ery systems have mostly resulted in a modest increase in
the therapeutic efficacy of DOX, usually in DOX sensitive
cancers, in preclinical and clinical studies. With the aim to
change the total DOX dose and to limit its high peak serum
concentration, we synthesized a doxorubicin-transferrin
(DOX-TRF) conjugate, a known approach to improve the
efficiency and delivery of anthracycline antibiotics [11,
12]. Transferrin (TRF) possesses several benefits over oth-
er drug carriers, which makes this protein an ideal candi-
date for improving the anti-tumor properties of DOX. First-
ly, it is not immunogenic, secondly, it is involved in iron
uptake and the regulation of cellular growth and, thirdly,
the expression of its receptors is significantly upregulated
in a variety of malignancies. As a result, the conjugation of
anticancer drugs with TRF may result in the delivery of
cytotoxic agents directly to neoplastic cells, with a limited
damage to normal cells [13].
Recently, we reported that DOX-TRF can overcome re-
sistance of cancer cells to conventional chemotherapy reg-
imens involving anthracycline drugs [14]. As yet, however,
little is known about its potency to induce programmed cell
death (apoptosis) in different types of cancer cells. Here,
we addressed the question whether free radicals can partic-
ipate in apoptosis induction by DOX-TRF using spectro-
metric, spectrofluorimetric, immunoenzymatic and micro-
scopic methods. Specifically, we monitored the time-
course of apoptotic and necrotic events, i.e., the production
of reactive oxygen species (ROS), changes in mitochondri-
al membrane potential (Δψm), changes in the level of in-
tracellular calcium, release of cytochrome c to the cytosol,
as well as morphological changes in both leukemia and
normal cells in the presence and absence of an antioxidant,
N-acetylcysteine (NAC). We show that DOX-TRF is more
cytotoxic towards leukemia cells than normal blood cells.
Our results indicate that the induction of apoptosis by
DOX-TRF in human leukemia cells is related to the gen-
eration of free radicals and a perturbation of their redox
homeostasis.
2 Materials and methods
2.1 Reagents and chemicals
RPMI-1640 culture medium, fetal bovine serum (FBS),
penicillin-streptomycin antibiotics, L-glutamine and
phosphate-buffered saline (PBS) were purchased from
Lonza (Lievres, Belgium), whereas doxorubicin (DOX)
was purchased from Sequoia Research Products
(Pangbourne, United Kingdom). The XTT assay kit,
H2DCF-DA, JC-1, and all reagents for carrying out the
conjugation procedure were purchased from Sigma-
Aldrich chemicals (Darmstadt, Germany). DOX was
coupled to TRF using a modified conjugation procedure
developed by Berczi et al. [15] and the conjugate ob-
tained was analyzed by mass spectrometry [16]. Cyto-
chrome c, YO-PRO-1 and Fluo-4 AM assay kits were
obtained from Invitrogen (United Kingdom). The other
chemicals were purchased from POCH S.A. (Gliwice,
Poland) if not otherwise indicated. The tissue culture
dishes were purchased from Corning (New York, USA).
2.2 Cell lines and primary blood cells
Three human leukemia-derived cell lines were used for
the in vitro studies: the acute lymphoblastic leukemia-
d e r i v e d c e l l l i n e CCRF -CEM , t h e c h r o n i c
erythroleukemia-derived cell l ine K562 and its
doxorubicin-resistant derivative cell line K562/DOX
[14]. In all experiments normal peripheral blood mono-
nuclear cells (PBMC) were included. These latter cells
were isolated from blood obtained from healthy young
(23–35 years) non-smoking men by centrifugation in a
Histopaque density gradient (300 g for 30 min at 22 °C).
Both normal and leukemic cells were cultured in RPMI-
1640 medium supplemented with L-glutamine (4 mM),
penicillin (100 U/ml), streptomycin (100 μg/ml) and
10 % v/v FBS using standard conditions, i.e., at 37 °C
in a humidified atmosphere containing 5 % CO2. In all
experiments, cells in a logarithmic growth phase were
used. The K562/DOX cell line was grown in the pres-
ence of 0.02 μM DOX as a selection agent. All cell lines
were monitored periodically for mycoplasma contamina-
tion. In some of the experiments, cells were pre-
incubated with the antioxidant N-acetylcysteine (NAC),
3 mM for 1 h, after which DOX or DOX-TRF at the
appropriate concentrations were added and the incuba-
tion was continued for the required period of time under
the same conditions. In the control experiments, cells
were treated with a corresponding volume of PBS
(instead of drugs or antioxidants) according to the same
schedule.
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2.3 Quantification of viable cells by XTT assay
The principle of the XTT assay is that viable cells reduce the
tetrazolium salt XTT (2,3-bis(2-methyloxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5 carboxanilide (Sigma-
Aldrich) to an orange-colored water-soluble product [17].
Here, 104 CCRF-CEM, K562 and K562/DOX cells or 105
PBMC cells were seeded in each well of a 96-well microplate
in 0.1 ml culture medium. Next, 0.05 ml DOX or DOX-TRF
at different concentrations were added to the appropriate
wells, and the cells were incubated with these drugs for
72 h. At the end of this incubation period, the cells were
centrifuged (230 g for 10 min at 4 °C) and the medium was
gently removed. Subsequently, 0.05 ml XTTat a final concen-
tration of 0.3 mg/ml in medium was added to each well and
the microplates were incubated for another 4 h. The resulting
reduction of XTTwas measured at 492 nm using a microtitre
plate reader (Awareness Technology Inc., USA). The percent-
age of viable cells was calculated by comparing the reduction
of XTT in drug treated cells to that in the untreated control
cells. The cytotoxicity was expressed as IC50, which is the
concentration at which the agent reduces the cell viability by
50% relative to the control cells. These values were calculated
using GraphPad Prism 4.03 software (GraphPad Inc.).
2.4 ROS formation assay
To measure intracellular reactive oxygen species (ROS) for-
mation, the fluorescent probe dichlorodihydrofluorescein
diacetate (H2DCF-DA) was used. Briefly, PBMC, CCRF-
CEM, K562 and K562/DOX cells were seeded in 96-well
plates and incubated with drugs (DOX or DOX-TRF) for 3,
6, 12, 24, 48 and 72 h. Next, the cells were incubated with
5 μMH2DCF-DA at 37 °C for 30 min [18] and ROS fluores-
cence (DCF) was measured using a Fluoroskan Ascent FL
microplate reader (Labsystems, Sweden).
2.5 YO-PRO-1 iodide/propidium iodide apoptosis assay
During apoptosis, cell membranes become permeable to the
green fluorescence dye YO-PRO-1 iodide, whereas they are
not permeable to the red fluorescent dye propidium iodide
(PI). After DOX or DOX-TRF treatment, a mixture of YO-
PRO-1 iodide and PI (0.1 μMeach) was added to the cells and
the samples were incubated for 20 min on ice. Next, the sam-
ples were analyzed by flow cytometry (LSR II, Becton Dick-
inson) with an excitation at 488 nm to visualize the YO-PRO-
1 green fluorescence and PI red fluorescence. Whereas after
this treatment living cells exhibit a low level of green fluores-
cence, apoptotic cells gradually exhibit higher levels of green
fluorescence. Dead cells exhibit both green and red fluores-
cence. The negative controls consisted of untreated cells. As a
positive apoptotic control, cells were incubated with 10 μM
campthotecin. The percentage of apoptosis was defined as the
percent of YO-PRO-1 stained cells within the cell population
of interest. Data were recorded for a total of 10,000 events per
sample and analyzed.
2.6 Intracellular calcium concentration assay
After subjection to different treatment regimens with DOX or
DOX-TRF in 96-well plates, the respective cells were incu-
bated with 7 μM fluo-4 AM as reported before [18], previous-
ly dissolved in DMSO for 60 min at 37 °C. The resulting
fluorescence intensity was analyzed using a Fluoroskan As-
cent FL microplate reader (Labsystems, Sweden) at 485 nm
excitation and 525 nm emission wavelengths.
2.7 Mitochondrial membrane potential assay
Changes in mitochondrial membrane potential were assessed
by measuring the 1,1′,3,3′-tetraethylbenzimidazolcarbocyanine
iodide (JC-1) fluorescence intensity ratio as reported before
[19]. To this end, the cells were pre-incubated with 5 μM JC-
1 in HBSS (140 mM NaCl, 5 mM KCl, 0.8 mM MgCl2,
1.8 mM CaCl2, 1 mM Na2HPO4, 10 mM HEPES and 1 %
glucose) for 30 min. Next, the cells were centrifuged (300 g
for 30 min at 22 °C) and washed twice with HBSS. The
resulting fluorescence was measured on a Fluoroskan Ascent
plate reader with filter pairs of 530 nm/590 nm and 485 nm/
538 nm. The results are presented as the fluorescence ratio
measured at 530 nm/590 nm to that measured at 485 nm/
538 nm (dimer to monomer fluorescence) relative to the control
untreated cell fluorescence ratio, which was set at 100 %.
2.8 Cytochrome c release assay
To determine mitochondrial cytochrome c release, the cyto-
solic fractions of the cells were first separated from the mito-
chondrial fractions according to the manufacturer’s proce-
dures (BioVision, USA). Next, the cells were exposed to
DOX-TRF or DOX for 6, 12 or 24 h and collected by centri-
fugation at 600 g for 5 min at 4 °C. After homogenizing the
cell pellets with cytosol extraction buffer (BioVision, USA) on
ice for 40 min, the supernatant (cytosolic protein fraction) was
immediately stored at −70 °C until use for biochemical
analysis.
The level of cytochrome c in the cytosolic fraction was
measured using a Cytochrome c Assay kit (R&D Systems,
USA). This colorimetric assay was performed in clear 96-
well plates pre-coated with an anti-cytochrome c monoclonal
antibody, according to the manufacturer’s instructions [20].
Finally, the plates were read at 450 nm using a Cary 50 mi-
croplate reader (Cary, Melbourne, Australia).
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2.9 Statistical analyses
The data are expressed as a means ± S.D. Analysis of variance
(ANOVA) with Tukey post hoc test was used for multiple
comparisons. All statistical parameters were calculated using
the STATISTICA program (StatSoft, Tulsa, OK, USA). A p
value of < 0.05 was considered significant. The viability
curves were fitted according to the sigmoidal dose–response
model (four-parameter logistic equation) using the GraphPad
Prism 4.03 software (GraphPad Inc).
3 Results
3.1 Cytotoxicity of DOX and DOX-TRF in normal
and leukemia-derived cells
3.2 ROS production changes in DOX and DOX-TRF
treated normal and leukemia-derived cells
The time-course of reactive oxygen species (ROS) produc-
tion was assessed after incubation of normal PBMCs and
the leukemia-derived cell lines CCRF-CEM, K562 and
K562/DOX with DOX or DOX-TRF. A significant increase
of DCF fluorescence (see materials and methods) in PBMC
was observed after a 3–24 h incubation with DOX, and 24 h
after incubation with DOX-TRF (Table 1). ROS generation
in the leukemia-derived cells was maximal after a 12 h
treatment with DOX-TRF and increased ~1.3-fold in
CCRF-CEM cells and ~1.5-fold in K562 cells. No signifi-
cant differences in ROS levels were observed between the
DOX and DOX-TRF-treated human leukemia-derived
cells. However, DOX-TRF induced a 1.3-fold higher ROS
production in K562/DOX cells than DOX. In order to con-
firm that the ROS production was related to the cytotoxicity
of DOX and DOX-TRF, the cells were treated with the
antioxidant NAC. We found that pretreatment of the cells
with 3 μM NAC efficiently reduced the drug-induced in-
creases in ROS levels.
3.3 Apoptosis and necrosis changes in DOX
and DOX-TRF treated normal and leukemia-derived cells
The ability of DOX and DOX-TRF to induce apoptosis or
necrosis in normal PBMCs and the leukemia-derived cell
lines CCRF-CEM, K562 and K562/DOX was estimated
after treatment of the cells up to 72 h with doses corre-
sponding to the respective IC50 values. Subsequent flow
cytometry after YO-PRO-1/PI double staining allowed
the distinction of three cell populations: living cells (green
fluorescence), apoptotic cells (yellow fluorescence) and
Fig. 1 Representative dose–response curves following exposure to DOX
versus DOX-TRF of PBMC, CCRF-CEM, K562 and K562/DOX cells
+/− NAC. Cell survival was assessed by XTT assay. (*) p < 0.05, the
effect of DOX and DOX-TRF on the viability of leukemia-derived and
PBMC cells; (#) p < 0.05 changes between the samples pre-incubated
with NAC. The values represent the mean ± SD of five independent
experiments
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The cytotoxicity of DOX and DOX-TRF was assessed in
normal peripheral blood-derived mononuclear cells
(PBMCs) and the leukemia-derived cell lines CCRF-CEM,
K562 and K562/DOX using a XTT assay. We found that
both compounds caused a dose-dependent decrease in cell
viability in the normal and leukemia-derived cells (Fig. 1).
DOX-TRF was two times less cytotoxic to the normal
PBMC than DOX. In contrast, the IC50 of DOX-TRF was
s i g n i f i c a n t l y l owe r t h a n t h a t o f DOX in t h e
leukemia-derived cells. The mean IC50 ratios were 2.4 for
CCRF-CEM and 3.7 for K562. The cytotoxic effect of
DOX-TRF over DOX was even more marked in the
K562/DOX cells (IC50 ratio of 9.9). Pre-incubation of the
leukemia-derived cells with the antioxidant NAC at 3 mM
resulted in a partial protection from DOX-TRF cytotoxicity
(~12–30 %), but more than that from DOX cytotoxicity
(~5–15 %).
necrotic cells (red-brown fluorescence) (Fig. 2). In parallel,
cellular morphologies were assessed using fluorescence
microscopy. By doing so, we found that DOX-TRF more
efficiently induced apoptotic hallmarks, such as chromatin
condensation and nuclear fragmentation, than DOX
(Fig. 3).
After shorter exposure times (3 h and 6 h), the levels of
apoptosis and necrosis in both the normal and the
leukemia-derived cells did not exceed 4–5 % of the total
cell numbers. Incubation of the cells for 12–72 h with DOX
or DOX-TRF increased the levels of apoptotic and necrotic
cells. As shown in Fig. 2, treatment of PBMC with DOX or
DOX-TRF caused an increase in the number of necrotic
cells of up to 30 % after 72 h treatment with the free drug
(DOX). The leukemia-derived cell lines exposed to DOX-
TRF reached maximal values in the number of apoptotic
cells (21.6 % for CCRF-CEM and 17.5 % for K562) after a
48 h incubation period. In K562/DOX cells the percentage
of apoptosis was highest at 48 h with both drugs (19.2 % for
DOX-TRF and 10.1 % for DOX), confirming that these
DOX-resistant cells treated with the conjugate died mostly
from apoptosis. As shown in Fig. 3, we found that the
number of apoptotic and necrotic cells in the normal and
leukemia-derived cells decreased in the presence of NAC.
These latter results suggest that ROS is involved in the
drug-induced apoptosis.
Table 1 Comparison of the
effects of DOX andDOX-TRF on
ROS production in PBMC and
leukemia-derived cells
Time of incubation [h] DOX DOX +NAC DOX-TRF DOX-TRF +NAC
CCRF-CEM
3 108.72 ± 8.41 103.17 ± 11.07 100.89 ± 5.50 97.82 ± 4.82
6 121.90 ± 4.65* 92.50 ± 8.22+ 126.27 ± 4.95* 93.99 ± 12.60+
12 134.91 ± 5.78* 108.79 ± 8.63+ 129.09 ± 2.86* 103.62 ± 4.45+
24 107.37 ± 3.49 99.85 ± 2.60 108.20 ± 4.90 102.00 ± 5.54
48 105.55 ± 3.88 95.33 ± 7.43 98.75 ± 10.17 96.11 ± 7.41
72 98.25 ± 5.64 101.23 ± 7.25 112.37 ± 4.72 95.82 ± 10.83
PBMC
3 122.58 ± 11.55* 114.29 ± 10.90 105.93 ± 11.95 103.66 ± 12.88
6 126.24 ± 10.53* 103.06 ± 6.37 107.17 ± 4.54 103.5 ± 2.68
12 118.23 ± 0.94* 94.07 ± 2.06 104.79 ± 1.57 91.83 ± 2.012
24 135.14 ± 9.82* 109.8 ± 1.92+ 125.94 ± 6.84* 107.4 ± 6.74+
48 106.47 ± 3.12 93.67 ± 4.57 96.65 ± 4.27 95.31 ± 4.54
72 104.94 ± 5.095 107.23 ± 7.73 107.05 ± 2.039 108.15 ± 9
K562
3 118.67 ± 5.69* 101.76 ± 3.64+ 94.61 ± 1.04 90.44 ± 1.25
6 130.65 ± 3.50* 106.24 ± 2.62+ 119.02 ± 2.33* 103.00 ± 1.65+
12 142.34 ± 4.53* 96.94 ± 2.04+ 152.27 ± 7.49* 89.50 ± 11.88+
24 101.43 ± 4.17 86.82 ± 3.72 132.81 ± 1.88* 103.59 ± 3.67+
48 93.17 ± 7.04 97.12 ± 6.36 105.42 ± 6.68 104.53 ± 10.8
72 101.62 ± 2.55 99.15 ± 3.34 105.85 ± 4.04 102.49 ± 7.66
K562/DOX
3 98.89 ± 2.86 99.85 ± 3.27 96.05 ± 2.9 98.92 ± 1.92
6 118.10 ± 3.45* 97.65 ± 3.28+ 124.51 ± 4.16* 97.35 ± 4.41+
12 113.90 ± 13.61* 91.06 ± 8.57+ 143.30 ± 6.74*# 87.01 ± 9.96+
24 98.22 ± 2.51 96.14 ± 5.41 117.67 ± 12.69*# 99.96 ± 1.61+
48 106.74 ± 2.69 101.93 ± 7.29 101.63 ± 6.09 82.41 ± 8.57
72 102.48 ± 8.5 82.87 ± 6.84 105.09 ± 11.24 87.98 ± 7.39
Cells were treated with IC50 doses of DOX or DOX-TRF for 3, 6, 12, 24, 48 and 72 h. The intensity of DCF
fluorescence in the control cells was set at 100 % (data not shown). Each value represents the average ± SD of
four independent experiments
*significantly different compared to control cells, p < 0.05
+ significant changes compared to samples pre-incubated with NAC and subsequently incubated with drugs,
p < 0.05
# significant differences between samples incubated with DOX and samples incubated with DOX-TRF, p < 0.05
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3.4 Intracellular Ca2+ concentration changes in DOX
and DOX-TRF treated normal and leukemia-derived cells
To investigate whether intracellular calcium ion changes were
involved in the apoptosis induced by DOX-TRF or DOX, we
assessed the level of free Ca2+ using the fluorescence probe
Fluo-4-AM. By doing so, we found that in PBMC after a 24 h
incubation with DOX and DOX-TRF the largest increases in
free cytoplasmic Ca2+ were similar, reaching a level of ~26 %
(Table 2). In the leukemia-derived cells, DOX-TRF induced
an increase in intracellular free Ca2+ during the first 24 h. At
this time point, the level of Ca2+ in the respective leukemia-
derived cells treated with IC50 DOX-TRF increased by ap-
proximately 30, 33 and 25 %, respectively (p < 0.05;
Table 2). Administration of the free radical scavenger NAC
3.5 Mitochondrial membrane potential changes in DOX
and DOX-TRF treated normal and leukemia-derived cells
Mitochondrial alterations after DOX or DOX-TRF treatment
were assessed by measuring changes in mitochondrial mem-
brane potential (Δψm) in normal PBMCs and the leukemia-
derived cell lines CCRF-CEM, K562 and K562/DOX using
the fluorescence probe JC-1. As a positive control, cells were
pre-incubated with CCCP, a protonophoric uncoupler of oxi-
dative phosphorylation, prior to JC-1 labeling, [21]. Upon
incubation with CCCP, a profound fall in membrane potential
was observed as expected, which was reflected by a decrease
in the JC-1 dimer to JC-1 monomer fluorescence ratio (data
not shown).
We found that DOX and DOX-TRF induced time-
dependent changes in Δψm (Table 3). In normal cells, Δψm
collapsed after a 6 h incubation with DOX (78 %) and after a
24 h incubation with DOX-TRF (86 %). The fluorescence
intensity of JC-1 decreased by 21 % at 6 h in CCRF-CEM
cells and by 26% at 12 h in K562 cells, whereas in k562/DOX
cells a maximal drop of Δψm was detected after a 24 h incu-
bation with DOX-TRF. After prolonged incubations (48–
72 h), the fluorescence intensity of JC-1 in all cell lines in-
creased to nearly 95 % compared to the control value. Pre-
incubation of the cells with NAC revealed a protective effect,
which indicates that the drop in mitochondrial membrane po-
tential was ROS-dependent. Additionally, we confirmed the
Δψm changes in drug-treated cells using fluorescence micros-
copy. Figure 4 shows that DOX-TRF treatment caused a re-
markable increase in green fluorescence of JC-1 monomers in
the leukemia-derived cells, indicating a reduction in mito-
chondrial membrane potential. In contrast, the red fluores-
cence of JC-1 dimers was seen mainly in untreated (control)
cells with a high mitochondrial potential.
3.6 Release of cytochrome c from mitochondria in DOX
and DOX-TRF treated normal and leukemia-derived cells
We monitored the efflux of cytochrome c from mitochondria
to cytosol using an ELISA assay kit at 6, 12 and 24 h in DOX-
Fig. 2 The effect of DOX and DOX-TRF without (left panel) and with
(right panel) NAC on the level of early and late apoptotic and necrotic
cells. NAC was added 1 h before DOX or DOX-TRF treatment. The
number of cells in apoptosis and necrosis were counted by flow
cytometry using YO-PRO-1 iodide/PI double staining, after which the
percentage fractions of the respective cells were calculated. Data are
mean ± SD of five samples. * p < 0.05 indicates significant differences
between drug-treated and control (untreated) cells; # p < 0.05 indicates
significant differences between cells treated with DOX and DOX-TRF; +
p < 0.05 indicates significant differences between DOX or DOX-TRF
treated cells and samples pre-incubated with NAC
Fig. 3 Morphological changes of PBMC, CCRF-CEM, K562 and
K562/DOX cells at 48 h after DOX or DOX-TRF treatment +/− NAC.
The cells were stained with PI and YO-PRO. In case of NAC treatment,
cells were pre-incubated for 1 h, then DOX or DOX-TRF was added and
the incubation was continued for up to 48 h. The cells were analyzed
under a fluorescence microscope at 400× magnification
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resulted in a marked reduction in the DOX-TRF and
DOX-induced changes in intracellular Ca2+.
TRF or DOX-treated normal PBMCs and the leukemia-
derived cell lines CCRF-CEM, K562 and K562/DOX. We
found that DOX induced a gradual increase in cytochrome c
in normal cells after a 12 h (38.9 ng/mg protein) and a 24 h
(50.8 ng/mg protein) incubation period (Fig. 5). DOX-TRF
treatment of PBMC led to an increase in cytochrome c
(40.2 ng/mg protein) after a 24 h incubation period. As shown
in Fig. 5, DOX-TRF induced the highest increases in cytosolic
cytochrome c after 24 h in CCRF-CEM and K562 cells (590.1
and 679.0 ng/mg protein), whereas a maximal level of cyto-
chrome c was released from the mitochondria after a 12 h
incubation with DOX (415.5 and 451.6 ng/mg protein in
CCRF-CEM and K562 cells, respectively).
In K562/DOX cells, DOX-TRF caused a release of cyto-
chrome c from mitochondria at all time points tested, while
DOX led to a maximal increase in cytosolic cytochrome c at
12 h, reaching 560.5 ng/mg protein. It appears, therefore, that
the cytosolic level of cytochrome c did not correlate with the
sensitivity of the cells to these compounds. Our studies do
confirm a time-dependent relationship between the decrease
in mitochondrial membrane potential and the release of cyto-
chrome c in cells treated with DOX-TRF.
4 Discussion
A major reason to find a way to deliver anticancer drugs di-
rectly to neoplastic cells is the rapid emergence of drug resis-
tant cell populations [14]. Ample literature data indicate that
over-expression of ATP-binding cassette (ABC) proteins is
Table 2 Effect of DOX and
DOX-TRF on intracellular Ca2+
levels in PBMC and leukemia-
derived cells
Time of incubation[h] DOX DOX+NAC DOX-TRF DOX-TRF +NAC
CCRF-CEM
3 95.67 ± 2.86 96.95 ± 7.52 95.67 ± 2.86 90.45 ± 3.39
6 109.09 ± 12.86 94.50 ± 8.22 121.90 ± 4.65 93.99 ± 7.60
12 125.10 ± 6.75* 102.74 ± 2.84+ 123.61 ± 8.86* 92.37 ± 7.78+
24 111.47 ± 3.62 98.23 ± 8.64 125.61 ± 4.90* 99.34 ± 6.87+
48 94.00 ± 6.70 103.00 ± 13.48 102.00 ± 13.40 101.00 ± 7.91
72 98.58 ± 1.50 100.40 ± 2.70 98.57 ± 5.64 100.8 ± 9.49
PBMC
3 99.35 ± 3.02 100.85 ± 12.35 100.06 ± 10.00 102.65 ± 7.69
6 111.17 ± 7.21 91.55 ± 14.51 94.29 ± 14.53 97.55 ± 5.85
12 119.69 ± 8.67* 100.37 ± 4.52+ 113.76 ± 0.81 100.35 ± 3.60
24 125.94 ± 10.41* 99.83 ± 10.61+ 126.07 ± 4.13* 95.35 ± 4.47+
48 100.01 ± 3.50 102.71 ± 4.90 116.37 ± 1.58* 100.37 ± 1.49+
72 97.82 ± 4.08 103.75 ± 8.35 100.36 ± 1.52 87.9 ± 8.02
K562
3 99.67 ± 2.86 96.95 ± 17.52 98.31 ± 12.37 95.45 ± 13.39
6 104.71 ± 6.88 101.01 ± 3.38 98.47 ± 9.89 97.45 ± 2.80
12 129.09 ± 9.86* 82.50 ± 8.22+ 117.90 ± 4.65* 93.99 ± 12.60+
24 98.34 ± 6.49 103.80 ± 5.39 133.43 ± 7.36*# 105.47 ± 1.83+
48 101.16 ± 5.41 97.92 ± 3.40 98.81 ± 3.00 102.08 ± 7.49
72 99.27 ± 5.73 94.63 ± 7.62 110.90 ± 4.35 102.34 ± 4.16
K562/DOX
3 99.5 ± 7.90 102.90 ± 3.40 98.10 ± 4.70 100.60 ± 6.80
6 119.9 ± 6.70 101.80 ± 5.10 95.30 ± 8.10 97.30 ± 4.90
12 122.62 ± 1.42 97.53 ± 1.76 126.81 ± 9.53* 96.54 ± 3.84+
24 109.46 ± 9.04 99.28 ± 5.60 133.42 ± 11.40*# 90.05 ± 8.40+
48 92.42 ± 11.40 97.85 ± 6.20 118.11 ± 10.76* 97.04 ± 5.83+
72 97.65 ± 10.48 97.05 ± 6.27 107.44 ± 13.05 98.81 ± 7.47
The intensity of Fluo- 4 AM fluorescence in the control cells was set at 100 % (data not shown). Each value
represents the mean ± SD of three independent experiments
*significantly different compared to control cells, p < 0.05
+ significant differences between DOX or DOX-TRF treated cells and samples pre-incubated with NAC, p < 0.05
# significant differences between samples incubated with DOX and samples incubated with DOX-TRF, p < 0.05
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closely related to increases in drug resistance [22–24]. Clearly,
there is a strong need to develop new ways to overcome drug
resistance e.g. by using specific drug carriers, such as lipo-
somes, dendrimers, nanoparticles or plasma proteins [25].
Previously, we showed that there is a relationship between
an increased cytotoxicity of the DOX-TRF conjugate and its
effect on the functionality of P-glycoprotein, one of the most
important ABC transporters [14]. We anticipate that due to a
different mode of action of the DOX-TRF conjugate, it may
be able to circumvent therapeutic complications such as
cardiotoxicity, nephrotoxicity and drug resistance. As yet,
however, little is known about the type of cell death provoked
by DOX-TRF. Therefore, we set out to analyze the induction
of cell death by DOX-TRF in relation to the generation of free
radicals (ROS). We found that DOX-TRF was able to induce
both apoptosis and necrosis in the cells tested. Prolonged
incubation with DOX-TRF resulted in a higher apoptotic rate
compared to a similar incubation with DOX. ROS generation
was found to be partially associated with DOX-TRF and DOX
cytotoxicity. In DOX-TRF or DOX treated leukemia-derived
cells, ROSwere produced partly as normalmetabolic products
and partly through the activation of ROS-producing enzymes.
DOX-TRF was most toxic in K562/DOX cells, which are
resistant to DOX. K562 and CCRF-CEM cells were 2.6 and
4 times less sensitive to DOX than to DOX-TRF. In
K562/DOX cells, DOX-TRFwas 10-fold more cytotoxic than
DOX. Its IC50 in normal blood cells exceeded 1000 nM, indi-
cating that DOX-TRF may cause greater harm to leukemic
cells than to PBMC.
It has amply been shown that ROS generation by antican-
cer drugs and the resulting oxidative stress are involved in the
initiation and/or execution phases of apoptosis [26, 27]. Here
Table 3 Mitochondrial
membrane potential changes in
PBMC and leukemia-derived
cells after treatment with DOX or
DOX-TRF
Time of incubation [h] DOX DOX+NAC DOX-TRF DOX-TRF +NAC
CCRF-CEM
3 98.90 ± 9.00 98.84 ± 2.70 97.81 ± 1.94 99.80 ± 10.50
6 79.95 ± 8.94* 97.16 ± 3.13+ 82.84 ± 4.58* 98.63 ± 5.02+
12 75.10 ± 6.75* 102.74 ± 2.84+ 72.61 ± 2.86* 101.34 ± 7.78+
24 98.47 ± 3.62 98.23 ± 8.64 95.61 ± 4.90 99.34 ± 6.87
48 94.00 ± 6.70 103. 00 ± 13.48 102. 00 ± 13.40 101. 00 ± 7.91
72 98.58 ± 1.50 100.40 ± 2.70 98.57 ± 5.64 100.80 ± 9.49
PBMC
3 107.75 ± 5.63 105.34 ± 4.40 100.51 ± 10.77 106.93 ± 6.10
6 78.33 ± 8.78* 92.91 ± 2.24 107.98 ± 7.30 104.96 ± 9.04
12 80.58 ± 4.56* 102.53 ± 4.42+ 97.90 ± 4.88 104.24 ± 5.58
24 89.34 ± 3.65 102.18 ± 3.28 86.61 ± 5.21* 104.53 ± 1.24+
48 100. 00 ± 4.68 106.04 ± 5.77 95.97 ± 5.19 102.65 ± 3.73
72 109.71 ± 4.27 104.30 ± 2.70 95.19 ± 3.19 109.00 ± 7.28
K562
3 98.58 ± 1.50 100.40 ± 2.70 98.57 ± 5.64 100.80 ± 9.49
6 80.91 ± 5.11* 102.00 ± 3.40+ 83.34 ± 4.60* 99.30 ± 5.60+
12 79.93 ± 5.89* 101.19 ± 9.09+ 74.87 ± 4.68* 97.31 ± 5.36+
24 90.00 ± 6.22 100.98 ± 3.84 83.00 ± 4.41* 102.78 ± 5.42+
48 93.06 ± 7.81 98.92 ± 9.46 97.91 ± 3.37 97.36 ± 2.60
72 98.74 ± 7.39 101.92 ± 5.13 92.78 ± 5.90 101.18 ± 4.49
K562/DOX
3 100.68 ± 2.52 106.39 ± 4.09 93.27 ± 3.94 103.21 ± 2.57
6 96.97 ± 0.74 100.78 ± 10.39 99.95 ± 14.09 99.89 ± 6.26
12 80.07 ± 4.17* 98.07 ± 3.03+ 75.48 ± 5.16* 94.38 ± 6.64+
24 85.25 ± 4.93* 101.61 ± 7.44+ 67.95 ± 5.53*# 103.37 ± 6.88+
48 108.60 ± 2.32 109.75 ± 1.17 93.89 ± 2.97 104.78 ± 5.50
72 104.36 ± 1.70 99.83 ± 6.99 102.44 ± 7.36 100.20 ± 3.90
Each value represents the mean ± SD of six separate experiments
*significantly different compared to the respective control cells (taken as 100 %, data not shown), p < 0.05
+ significant differences between DOX or DOX-TRF treated cells and samples pre-incubated with NAC, p < 0.05
# significant differences between samples incubated with DOX and samples incubated with DOX-TRF, p < 0.05
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we show that addition of the free radical scavenger NAC to the
DOX formulations significantly decreased the fraction of ap-
optotic and necrotic cells, including the apoptotic features.
Our results are in agreement with those of Rogalska et al.
[18], who showed that aclarubicin was able to generate free
radicals and, as a consequence, to affect the apoptotic process
in human solid tumors. Given that anthracyclines encompass
both para-quinone and para-hydroquinone moieties, ROS
generation may be initiated through reduction or oxidation
of the drug [21, 28].
ROS l e v e l s w e r e a s s e s s e d t h r o u g h 2 ′ , 7 ′ -
dichlorodihydrofluorescein diacetate (DCF) fluorescence
measurements. We found that DOX-TRF treatment led to
the production of ROS after a prolonged incubation time in
Fig. 5 Release of cytochrome c from mitochondria in PBMC and
leukemia-derived cells after treatment with DOX or DOX-TRF. Results
represent the mean ± SD of three independent experiments. * p < 0.05
indicates significantly different from the control; # p < 0.05 indicates
significant difference between the samples incubated with DOX and
DOX-TRF
Fig. 4 Fluorescent microscopy images of control cells, incubated with
PBS, and cells treated with IC50 concentrations of DOX or DOX-TRF for
12 h at 37 °C +/−NAC. Red fluorescence of JC-1 dimers is present in cell
areas with a high mitochondrial membrane potential, while green
fluorescence of JC-monomers is prevalent in cell areas with a low
mitochondrial membrane potential. The cells were analyzed under a
fluorescence microscope at 400× magnification
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leukemic cells, while DOX caused an increase of DCF fluo-
rescence after 6 and 12 h incubation in the leukemia-derived
cell lines and after a 24 h incubation in PBMCs. A lower
toxicity of free radicals to normal cells (i.e., cardiomyocytes
and endothelial cells) has previously been observed after in-
cubation with an epirubicin conjugate of polyethyleneglycol
(PEG) and nitric oxide. While this compound was toxic to
Caco2 cancer cells, normal cells remained intact during treat-
ment [29].
Part of our current study was focused on the biochemical
changes induced during apoptosis by DOX-TRF in normal
and leukemia-derived cells. We investigated mitochondrial
membrane potential, the level of intracellular Ca2+ and the
intracellular fraction of cytochrome c. Dissipation of Δψm is
one of the markers for a mitochondrial involvement in apo-
ptosis [30]. Our data show that a drop in mitochondrial mem-
brane potential (Δψm) occurred during the first 6 h following
DOX or DOX-TRF treatment in the leukemia-derived cell
lines tested. In PBMC and in the doxorubicin-resistant
erythroleukemia cell line K562/DOX, the Δψm decreased
after 24 and 12 h of DOX-TRF treatment, respectively. After
a prolonged incubation time (48–72 h), irrespective of cell
type, the Δψm gradually recovered. These observations sug-
gest that Δψm loss is an early event in the apoptotic cascade,
induced by both DOX and DOX-TRF. We also found that
DOX-TRFwasmore effective thanDOX in the depolarization
of mitochondria in malignant cells. Previously, a decrease in
Δψm was also observed after DOX-induced apoptosis in hu-
man mammary adenocarcinoma cells (MTLn3), in porcine
renal proximal tubular cells (LLC-PK1) [31] and in various
other human tumor cells after amrubicin treatment [32].
It has amply been suggested that free Ca2+ is one of the
most important signaling agents in human cancer cells [33]. A
rise in intracellular Ca2+ may be one of the triggering events
that lead to cell damage or apoptosis [34]. Kania et al. [35]
have shown that aclarubicin can induce an increase in the
intracellular pool of Ca2+ after a 4 h incubation of normal
(S2) and trisomic (BB) diabetic fibroblasts, whereas
Brachwitz et al. [36] observed an increase in Ca2+ in the hu-
Another crucial event in the path to apoptosis is the release
of cytochrome c from mitochondria [36]. Cytochrome c is
normally located in the intermembranous space of the mito-
chondria, loosely bound to the inner membrane. Several au-
thors have reported a release of cytochrome c to the cytosol
upon DOX treatment [37]. Although apoptosis can occur via
cytochrome c-independent mechanisms, it is well established
that in most cell types, once cytochrome c is released into the
cytosol, it interacts with APAF1 and procaspase-9, leading to
the generation of active caspase-9, which is capable to proteo-
lytically activate caspase-3 [38, 39]. As shown by many au-
thors, anthracyclines can induce apoptosis in cancer cells by
increasing the cytosolic fraction of cytochrome c [40]. Here,
we found that both DOX-TRF and DOX can cause an efflux
of cytochrome c from mitochondria.
The ability of DOX to release cytochrome c into the cytosol
has been documented by Childs et al. [41]. They reported that
the assessment of apoptosis by determination of the amount of
cytosolic cytochrome c indicated that doxorubicin can induce
oxidative stress and mitochondria-mediated apoptosis, as well
as adaptive responses by mitochondria to protect cardiac
myocytes in vivo.
We conclude that DOX-TRF can induce ROS-dependent
changes characteristic of apoptosis in human leukemia-
derived cells. We found that, compared to DOX, DOX-TRF
was less toxic to normal peripheral blood mononuclear cells
and significantly more cytotoxic to leukemia-derived cells.
Transferrin (TRF) serves a promising and efficacious carrier
for the targeted delivery of doxorubicin.
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